Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging, formulation, or excipients are unique characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Montero-Vilchez, Trinidad, Cuenca-Barrales, Carlos, Rodriguez-Tejero, Andrea, Martinez-Lopez, Antonio, Arias-Santiago, Salvador, Molina-Leyva, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879480/
https://www.ncbi.nlm.nih.gov/pubmed/35207280
http://dx.doi.org/10.3390/jcm11041007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879480/
https://www.ncbi.nlm.nih.gov/pubmed/35207280
http://dx.doi.org/10.3390/jcm11041007

Ejemplares similares